Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019
Aikaterini Bilitou,1 John Were,2 Archie Farrer,2 Adrian Rabe,2,3 Simon Wan Yau Ming,2 Inaam Haq,1 Kyle Dunton4 1Daiichi Sankyo Europe GmbH, Munich, Bayern, Germany; 2Health iQ Ltd, London, UK; 3Imperial College London, London, UK; 4Daiichi Sankyo UK Ltd, Uxbridge Business Park, Uxbridge, UKCorrespon...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-04-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/prevalence-and-patient-outcomes-of-adult-primary-hypercholesterolemia--peer-reviewed-fulltext-article-CEOR |
| _version_ | 1811271905190084608 |
|---|---|
| author | Bilitou A Were J Farrer A Rabe A Ming SWY Haq I Dunton K |
| author_facet | Bilitou A Were J Farrer A Rabe A Ming SWY Haq I Dunton K |
| author_sort | Bilitou A |
| collection | DOAJ |
| description | Aikaterini Bilitou,1 John Were,2 Archie Farrer,2 Adrian Rabe,2,3 Simon Wan Yau Ming,2 Inaam Haq,1 Kyle Dunton4 1Daiichi Sankyo Europe GmbH, Munich, Bayern, Germany; 2Health iQ Ltd, London, UK; 3Imperial College London, London, UK; 4Daiichi Sankyo UK Ltd, Uxbridge Business Park, Uxbridge, UKCorrespondence: Aikaterini Bilitou, Health Economics and Outcomes Research, Daiichi Sankyo Europe GmbH, Zielstattstrasse 48, Munich, 81379, Bayern, Germany, Tel +49 897 808802, Email aikaterini.bilitou@daiichi-sankyo.euBackground: Guidelines for the management of dyslipidemias recommend intensive low-density lipoprotein (LDL-C) control through lifestyle advice and lipid-lowering drugs to reduce the risk of cardiovascular disease (CVD).Objective: This retrospective study aimed to characterize the adult primary care population with primary hypercholesterolemia (PH)/mixed dyslipidemia (MD).Methods: Data on adults with PH/MD between 1 January 2009 and 31 December 2019 in the UK were extracted from linked primary Clinical Practice Research Datalink (CPRD) and secondary care (Hospital Episode Statistics) datasets and analyzed.Results: A total of 279,221 patients met the inclusion criteria. Mean follow-up was 8.6 years. Crude prevalence of PH/MD increased from 13.5% in 2009 to 23.5% by 2019. The incidence decreased from 176 to 49 per 100,000 population. Mean age of the cohort was 58 years, baseline LDL-C was 4.32 mmol/L, 19.6% had atherosclerotic CVD, 30.1% diabetes, and 8.5% heterozygous familial hypercholesterolemia. Estimated LDL-C reductions of 40% and 50% were achieved in 2.6% and 2.3% of patients, respectively. Most received moderate-intensity statins as monotherapy (62.4%); high-intensity statins were used less frequently (24.3% as initial treatment). Less than 10% of patients received ezetimibe plus statins of different intensities.Conclusion: The prevalence of dyslipidemia doubled between 2009 and 2019, likely due to more systematic identification of PH/MD. A large proportion of patients with PH/MD are of high and very high CV risk, remain suboptimally treated in terms of lipid lowering, and may experience CV events with associated non-negligible clinical and economic sequelae. Despite intensive LDL-C-lowering recommendations, these do not translate in clinical practice to the wider population.Keywords: lipid management, atherosclerosis, cardiovascular disease, NICE guidelines |
| first_indexed | 2024-04-12T22:30:34Z |
| format | Article |
| id | doaj.art-62e042757b5a4637aa4f9198da3cdccc |
| institution | Directory Open Access Journal |
| issn | 1178-6981 |
| language | English |
| last_indexed | 2024-04-12T22:30:34Z |
| publishDate | 2022-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ClinicoEconomics and Outcomes Research |
| spelling | doaj.art-62e042757b5a4637aa4f9198da3cdccc2022-12-22T03:13:59ZengDove Medical PressClinicoEconomics and Outcomes Research1178-69812022-04-01Volume 1418920374239Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019Bilitou AWere JFarrer ARabe AMing SWYHaq IDunton KAikaterini Bilitou,1 John Were,2 Archie Farrer,2 Adrian Rabe,2,3 Simon Wan Yau Ming,2 Inaam Haq,1 Kyle Dunton4 1Daiichi Sankyo Europe GmbH, Munich, Bayern, Germany; 2Health iQ Ltd, London, UK; 3Imperial College London, London, UK; 4Daiichi Sankyo UK Ltd, Uxbridge Business Park, Uxbridge, UKCorrespondence: Aikaterini Bilitou, Health Economics and Outcomes Research, Daiichi Sankyo Europe GmbH, Zielstattstrasse 48, Munich, 81379, Bayern, Germany, Tel +49 897 808802, Email aikaterini.bilitou@daiichi-sankyo.euBackground: Guidelines for the management of dyslipidemias recommend intensive low-density lipoprotein (LDL-C) control through lifestyle advice and lipid-lowering drugs to reduce the risk of cardiovascular disease (CVD).Objective: This retrospective study aimed to characterize the adult primary care population with primary hypercholesterolemia (PH)/mixed dyslipidemia (MD).Methods: Data on adults with PH/MD between 1 January 2009 and 31 December 2019 in the UK were extracted from linked primary Clinical Practice Research Datalink (CPRD) and secondary care (Hospital Episode Statistics) datasets and analyzed.Results: A total of 279,221 patients met the inclusion criteria. Mean follow-up was 8.6 years. Crude prevalence of PH/MD increased from 13.5% in 2009 to 23.5% by 2019. The incidence decreased from 176 to 49 per 100,000 population. Mean age of the cohort was 58 years, baseline LDL-C was 4.32 mmol/L, 19.6% had atherosclerotic CVD, 30.1% diabetes, and 8.5% heterozygous familial hypercholesterolemia. Estimated LDL-C reductions of 40% and 50% were achieved in 2.6% and 2.3% of patients, respectively. Most received moderate-intensity statins as monotherapy (62.4%); high-intensity statins were used less frequently (24.3% as initial treatment). Less than 10% of patients received ezetimibe plus statins of different intensities.Conclusion: The prevalence of dyslipidemia doubled between 2009 and 2019, likely due to more systematic identification of PH/MD. A large proportion of patients with PH/MD are of high and very high CV risk, remain suboptimally treated in terms of lipid lowering, and may experience CV events with associated non-negligible clinical and economic sequelae. Despite intensive LDL-C-lowering recommendations, these do not translate in clinical practice to the wider population.Keywords: lipid management, atherosclerosis, cardiovascular disease, NICE guidelineshttps://www.dovepress.com/prevalence-and-patient-outcomes-of-adult-primary-hypercholesterolemia--peer-reviewed-fulltext-article-CEORlipid managementatherosclerosiscardiovascular diseasenice guidelines |
| spellingShingle | Bilitou A Were J Farrer A Rabe A Ming SWY Haq I Dunton K Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019 ClinicoEconomics and Outcomes Research lipid management atherosclerosis cardiovascular disease nice guidelines |
| title | Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019 |
| title_full | Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019 |
| title_fullStr | Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019 |
| title_full_unstemmed | Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019 |
| title_short | Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019 |
| title_sort | prevalence and patient outcomes of adult primary hypercholesterolemia and dyslipidemia in the uk longitudinal retrospective study using a primary care dataset from 2009 to 2019 |
| topic | lipid management atherosclerosis cardiovascular disease nice guidelines |
| url | https://www.dovepress.com/prevalence-and-patient-outcomes-of-adult-primary-hypercholesterolemia--peer-reviewed-fulltext-article-CEOR |
| work_keys_str_mv | AT bilitoua prevalenceandpatientoutcomesofadultprimaryhypercholesterolemiaanddyslipidemiaintheuklongitudinalretrospectivestudyusingaprimarycaredatasetfrom2009to2019 AT werej prevalenceandpatientoutcomesofadultprimaryhypercholesterolemiaanddyslipidemiaintheuklongitudinalretrospectivestudyusingaprimarycaredatasetfrom2009to2019 AT farrera prevalenceandpatientoutcomesofadultprimaryhypercholesterolemiaanddyslipidemiaintheuklongitudinalretrospectivestudyusingaprimarycaredatasetfrom2009to2019 AT rabea prevalenceandpatientoutcomesofadultprimaryhypercholesterolemiaanddyslipidemiaintheuklongitudinalretrospectivestudyusingaprimarycaredatasetfrom2009to2019 AT mingswy prevalenceandpatientoutcomesofadultprimaryhypercholesterolemiaanddyslipidemiaintheuklongitudinalretrospectivestudyusingaprimarycaredatasetfrom2009to2019 AT haqi prevalenceandpatientoutcomesofadultprimaryhypercholesterolemiaanddyslipidemiaintheuklongitudinalretrospectivestudyusingaprimarycaredatasetfrom2009to2019 AT duntonk prevalenceandpatientoutcomesofadultprimaryhypercholesterolemiaanddyslipidemiaintheuklongitudinalretrospectivestudyusingaprimarycaredatasetfrom2009to2019 |